Skip to Main Content

Paper Details

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.
Nat Commun
26
2022
CDK4, CDK4/6, ER, ER breast cancer, ESR1, PI3K, PIK3CA, RB1, RB1 mutation, advanced estrogen receptor-positive breast cancer, alpelisib, breast cancer, estrogen, estrogen receptor, estrogen receptor-positive breast cancer cell lines, estrogen receptor-positive non-basal-like breast cancer, p16, patient, patient-derived xenografts, patients, ribociclib, tumors, xenografts
Author NameAffiliation
Abel Gonzalez-PerezInstitute for Research in Biomedicine (IRB Barcelona)
Abel Gonzalez-PerezUniversitat Pompeu Fabra
Alejandra BrunaPreclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research
Carlos Caldas
Rodrigo DienstmannVall d'Hebron Institute of Oncology
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona)
Nuria Lopez-BigasUniversitat Pompeu Fabra
Nuria Lopez-BigasInstitucio Catalana de Recerca i Estudis Avancats (ICREA)
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona)
Nuria Lopez-BigasUniversitat Pompeu Fabra
Nuria Lopez-BigasInstitucio Catalana de Recerca i Estudis Avancats (ICREA)
  • 1 - 11

Datasets

Release 1.2